Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea Pharmaceutica : Partner to File Marketing Authorization for Antifungal Drug in Japan

07/26/2021 | 03:05am EDT


© MT Newswires 2021
All news about BASILEA PHARMACEUTICA AG
09/17BASILEA PHARMACEUTICA : Bile Duct Cancer Drug Shows Improved Efficacy In Updated..
MT
09/17PRESS RELEASE : Basilea presents full safety and -2-
DJ
09/17PRESS RELEASE : Basilea presents full safety and efficacy data set on derazantin..
DJ
09/17Basilea presents full safety and efficacy data set on derazantinib in patient..
DJ
09/17Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Dera..
CI
08/17Basilea Pharmaceutica Ag Reports Earnings Results for the Half Year Ended Jun..
CI
08/17PRESS RELEASE : Basilea reports strong financial -3-
DJ
08/17PRESS RELEASE : Basilea reports strong financial -2-
DJ
08/17PRESS RELEASE : Basilea reports strong financial results for half-year 2021 with..
DJ
08/17BASILEA PHARMACEUTICA : reports strong financial results for half-year 2021 with..
AQ
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2021 136 M 146 M 146 M
Net income 2021 -21,5 M -23,1 M -23,1 M
Net Debt 2021 82,2 M 88,1 M 88,1 M
P/E ratio 2021 -23,3x
Yield 2021 -
Capitalization 569 M 611 M 610 M
EV / Sales 2021 4,77x
EV / Sales 2022 4,02x
Nbr of Employees 160
Free-Float 88,5%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 48,22 CHF
Average target price 87,60 CHF
Spread / Average Target 81,7%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Chief Financial Officer
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-9.28%611
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420